Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

North America Circular Polymers Market Set to Expand at 7.8% CAGR From 2026 to 2035

August 17, 2026

Fiberglass Doors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

August 17, 2026

RCMP help recover ancient Peruvian artifact in Montreal

August 17, 2026

Less than 20% of Canadians want to give U.S. ‘concessions,’ poll finds

August 17, 2026

Offshore Wind Market by Component, Water Depth, Foundation Type, Turbine Rating, and Region – Global Forecast to 2035

August 17, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Press Release

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

By News RoomJune 9, 20262 Mins Read
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Share
Facebook Twitter LinkedIn Pinterest Email

BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) — Alembic Therapeutics, LLC announces the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment of bacterial vaginal infections in females 12 years of age and older, from Exeltis USA, Inc. This acquisition represents an important milestone in Alembic Therapeutics’ ongoing commitment to expanding its women’s health portfolio and increasing patient access to proven treatment options. Through this transaction, Alembic Therapeutics assumes responsibility for the commercialization and distribution of NUVESSA in the United States.

NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is designed as a convenient single-dose, pre-filled disposable applicator, which delivers approximately 5g of gel containing 65mg of metronidazole, administered once a day at bedtime intravaginally. NUVESSA is contraindicated in persons who have shown hypersensitivity to metronidazole, parabens, any component of the formulation, or other nitroimidazole derivatives.

NUVESSA will continue to be available nationwide through retail and specialty pharmacy distribution channels. Healthcare providers can continue prescribing NUVESSA in accordance with the approved prescribing information for appropriate patients. The full prescribing information should be consulted for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.

Alembic Therapeutics is dedicated to delivering high-quality pharmaceutical products and innovative healthcare solutions that improve patient outcomes and expand access to care across multiple therapeutic categories.

Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
908-569-7456 • [email protected]
www.alembictherapeutics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c2b9304-e79b-43e8-8e2c-9cb1ad8774ae

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

North America Circular Polymers Market Set to Expand at 7.8% CAGR From 2026 to 2035

Fiberglass Doors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

Offshore Wind Market by Component, Water Depth, Foundation Type, Turbine Rating, and Region – Global Forecast to 2035

Following Billion-Dollar Funding Surges for Custom Inference Silicon and Liquid-Cooled Servers, New Study Maps AI Hardware Ecosystem Out to 2040

Diligent Robotics, a Serve Robotics Company, Begins Rolling Out Moxi 2.0

Rent a Bedside Table in Pune, Gurgaon and Hyderabad Instead of Buying in 2026 as ₹3,500–₹9,000 Purchases Lose to ₹102 a Month With Repairs, Relocation and Collection Included From Rentomojo

Glass Flake Coatings Competitive Landscape: Akzo Nobel, PPG, Sherwin-Williams and Jotun Advance Sustainable Solutions

TDECU Board Elects Lavonne Burke as New Chair

Glass Reintroduces G-Commerce, the AI-Powered Commerce Platform for the Public Sector

Editors Picks

Fiberglass Doors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

August 17, 2026

RCMP help recover ancient Peruvian artifact in Montreal

August 17, 2026

Less than 20% of Canadians want to give U.S. ‘concessions,’ poll finds

August 17, 2026

Offshore Wind Market by Component, Water Depth, Foundation Type, Turbine Rating, and Region – Global Forecast to 2035

August 17, 2026

Latest News

Apple ordered to stop scaring iPhone and iPad users away from third-party apps

August 17, 2026

Following Billion-Dollar Funding Surges for Custom Inference Silicon and Liquid-Cooled Servers, New Study Maps AI Hardware Ecosystem Out to 2040

August 17, 2026

Diligent Robotics, a Serve Robotics Company, Begins Rolling Out Moxi 2.0

August 17, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version